Compare Baker Hughes Co (BKR) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Bristol-Myers Squibb Co — how do they compare? Baker Hughes Co trades at $57.78 (market cap $57.32B), while Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 2× Baker Hughes Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BKR | BMY | |
|---|---|---|
Market Cap | $57.32B | $116.30B |
Sector | Energy | Health |
52-Week High | $69.67 | $62.37 |
52-Week Low | $38.68 | $42.60 |
Enterprise Value | $58.72B | $152.24B |
Dividend Yield | 1.59% | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
